schinazi

reViral hires non-executive director

pharmafile | April 28, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing reviral, schinazi 

Antiviral drug firm reViral has appointed Professor Raymond 
Schinazi as a non-executive director. 

Schinazi has had a long and prestigious career in the industry 
having founded several biotech companies including 
Pharmasset, where he chaired the board and directed the scientific research leading to the discovery of promising hepatitis C treatment Sovaldi.

Ken Powell, chairman and founder of reViral says: “We are very pleased to have attracted someone of Ray’s experience and
prestige to reViral. A world leader in nucleoside chemistry and biology,
 Ray’s discoveries have made a tangible impact on the quality of life and
welfare of society. His remarkable accomplishments and wealth of experience
 will be integral to reViral.” 

Advertisement

Newly-appointed Schinazi adds: “I look forward to working with the proven management
 team and am excited by the company’s highly promising programme and 
pipeline, as it expands into areas of high unmet need.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content